Loading organizations...
§ Private Profile · 161 E Michigan Ave Fl 4, Kalamazoo, Michigan, 49007, United States
Clinical-stage pharmaceutical company developing therapies for insulin resistance, Type 2 Diabetes, and MASLD/MASH.
Cirius Therapeutics has raised $40.0M across 1 funding round.
Key people at Cirius Therapeutics.
Cirius Therapeutics has raised $40.0M in total across 1 funding round.
Cirius Therapeutics is a clinical-stage pharmaceutical company developing therapies for diseases caused by insulin resistance, based in San Diego, California, and Kalamazoo, Michigan. The biotechnology firm focuses on treating metabolic conditions such as Type 2 Diabetes and metabolic dysfunction-associated fatty liver disease through its lead mitochondrial target program, MSDC-0602K. Operating with fewer than 25 employees, the enterprise has raised a total of $56.4 million across two equity financing rounds. This capitalization includes a $40 million Series A tranche backed by institutional investors such as Frazier Healthcare Partners, Novo A/S, and Adams Street Partners. The pre-revenue organization utilizes this venture capital funding to advance its clinical trials and pipeline of metabolic medications targeting nonalcoholic steatohepatitis. Cirius Therapeutics was originally established in 2015 before rebranding in 2016, and was co-founded by Jerry Colca and Rolf Kletzien.
Key people at Cirius Therapeutics.
Cirius Therapeutics has raised $40.0M in total across 1 funding round.
Cirius Therapeutics's investors include Daniel Estes, Nilesh Kumar, Adams Street Partners, Hopen Life Science Ventures, Renaissance Venture Capital Fund.
Cirius Therapeutics has raised $40.0M across 1 funding round. Most recently, it raised $40.0M Series A in April 2017.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Apr 11, 2017 | $40M Series A | Daniel Estes, Nilesh Kumar | Adams Street Partners, Hopen Life Science Ventures, Renaissance Venture Capital Fund | Announced |
Cirius Therapeutics is a clinical-stage biopharmaceutical company developing innovative small-molecule therapies targeting mitochondrial dysfunction to treat insulin resistance-driven diseases, including Type 2 Diabetes, obesity-related metabolic issues, and MASLD/MASH (formerly NASH).[1][2][4][5] Its lead candidate, azemiglitazone (MSDC-0602K), is an oral, once-daily second-generation insulin sensitizer that selectively modulates the mitochondrial pyruvate carrier (MPC) without activating PPAR-γ, avoiding safety issues of first-generation drugs like pioglitazone.[2][3] The company serves patients with chronic metabolic disorders, addressing overnutrition's cellular effects, and has shown promise in Phase 2 trials for MASH with fibrosis, with Phase 3 planning underway; it recently presented data on combinations with GLP-1 agonists like tirzepatide.[2][3][5]
Headquartered in San Diego, CA, and Kalamazoo, MI, Cirius has raised about $56.4M in funding, including a $40M Series A in 2017, supporting its pipeline momentum toward commercialization.[3][4]
Cirius Therapeutics was officially founded in 2016, building on research into thiazolidinediones (TZDs), first-generation insulin sensitizers for Type 2 Diabetes that showed NASH efficacy but had safety concerns like weight gain and heart risks.[3] The idea emerged from observations by researcher Ken Cusi, who demonstrated pioglitazone's benefits in NASH, prompting development of a safer MPC-targeted alternative.[3] CEO Bob Baltera leads the privately-held firm, with key scientific input from CSO Jerry Colca, who highlights the drug's design to exploit mitochondrial targets discovered in TZDs.[2]
Early traction came via a Series A round in April 2017, raising up to $40M led by Frazier Healthcare Partners and Novo A/S, joined by Adams Street Partners, Renaissance Venture Capital Fund, and Hopen Life Sciences Ventures.[3] This funded the EMMINENCE Phase 2b trial of MSDC-0602K in NASH patients with fibrosis, completed around 2019, paving the way for ongoing studies including 52-week trials in MASH with/without Type 2 Diabetes and recent combo data presentations.[2][3]
Cirius rides the wave of mitochondrial-targeted therapies in metabolic disease, capitalizing on surging demand for NASH/MASH and obesity treatments amid GLP-1 dominance (e.g., tirzepatide).[2][5] Timing aligns with regulatory shifts—like FDA's MASH breakthrough designations—and epidemiological pressures from rising insulin resistance, affecting millions with Type 2 Diabetes and liver fibrosis.[1][3][4] Market forces favor oral add-ons to injectables, where azemiglitazone's combo potential could enhance weight loss durability and fibrosis resolution without first-gen side effects.[2]
The company influences biotech by reviving TZD promise through precision targeting, contributing to a ecosystem shift toward cellular-level interventions in cardiometabolic epidemics, potentially enabling broader access via affordable orals.[2][3]
Cirius is primed for Phase 3 readouts and partnerships, with azemiglitazone eyeing approvals in MASH and Diabetes by late 2020s, boosted by GLP-1 combo data at ADA 2025.[2][5] Trends like mitochondrial drugging and oral-injectable synergies will propel it, amid $100B+ obesity markets. Its influence could grow via acquisitions or expansions into related indications, fulfilling insulin sensitizers' unmet potential in a post-GLP-1 era—transforming Cirius from clinical contender to metabolic therapy staple.[2][3]
